ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BCTX BriaCell Therapeutics Corporation

3.46
0.06 (1.76%)
Feb 29 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 76,644
Bid Price 3.30
Ask Price 3.56
News -
Day High 3.55

Low
3.03

52 Week Range

High
7.75

Day Low 3.37
Company Name Stock Ticker Symbol Market Type
BriaCell Therapeutics Corporation BCTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 1.76% 3.46 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.37 3.37 3.55 3.46 3.40
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
668 76,644 $ 3.48 $ 266,614 - 3.03 - 7.75
Last Trade Time Type Quantity Stock Price Currency
18:14:27 5 $ 3.50 USD

BriaCell Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
169.41M 15.98M - 0 -20.3M -1.27 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

BriaCell Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BCTX Message Board. Create One! See More Posts on BCTX Message Board See More Message Board Posts

Historical BCTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.573.733.163.4069,346-0.11-3.08%
1 Month4.114.353.033.6687,206-0.65-15.82%
3 Months5.115.973.034.37103,855-1.65-32.29%
6 Months7.487.483.034.8097,366-4.02-53.74%
1 Year6.837.753.035.85105,388-3.37-49.34%
3 Years3.8512.472.81496.65929,200-0.39-10.13%
5 Years4.2412.472.81496.63931,915-0.78-18.40%

BriaCell Therapeutics Description

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

Your Recent History

Delayed Upgrade Clock